Key Takeaways BSX is set to report Q4 results on Feb. 4, with revenues seen up 15.4% and earnings expected to rise 11.4%. BSX's MedSurg unit is expected to grow 11.4%, led by Endoscopy, Urology gains and Neuromodulation. BSX's Cardiovascular sales are seen up 17.5% on WATCHMAN uptake, FARAPULSE demand and strength. Boston Scientific (BSX) is slated to report fourth-quarter 2025 results on Feb. 4, before market open.The renowned medical device manufacturer posted earnings per share (EPS) of 75 cents in the l ...

Core Insights - Boston Scientific (BSX) and Resmed (RMD) are significant players in the global medical devices market, with market capitalizations of $142.4 billion and $35.72 billion, respectively [2] - The medical devices market is projected to grow at nearly 7% CAGR from 2025 to 2030, prompting an evaluation of investment opportunities in both companies [3] Boston Scientific Overview - Boston Scientific is experiencing strong performance in its Cardiovascular and MedSurg segments, with expectations for above-market growth through 2025-2026 [4] - The WATCHMAN device is a leading product in percutaneous left atrial appendage closure (LAAC), with a projected market expansion of approximately 20% in the coming years [5] - The company is gaining market share in electrophysiology, particularly with the FARAPULSE Pulsed Field Ablation System, which received FDA approval for expanded use in July 2025 [6] - Recent acquisitions, including Intera Oncology and Elutia's BioEnvelope business, support Boston Scientific's growth strategy and expansion into high-growth areas [7] - Emerging markets accounted for 15% of Boston Scientific's consolidated net sales in the first nine months of 2025, indicating significant long-term growth potential [8] Resmed Overview - Resmed is witnessing strong demand for its mask portfolio, including the AirFit and AirTouch ranges, and is focusing on direct-to-consumer markets in regions like China and India [9] - The company has launched new variants of its AirTouch F30i mask and continues to see strong sales from its AirSense device platforms [9] - Resmed is advancing AI integration in its digital health products, including the launch of the personal sleep health digital assistant, Dawn, in the U.S. [11] - The company is optimizing operations to improve gross margins and has made acquisitions like Somnoware and Ectosense to support its 2030 growth strategy [12] Financial Estimates and Performance - The Zacks Consensus Estimate for Boston Scientific's 2025 EPS indicates a year-over-year increase of 21.1% to $3.04, with a slight upward revision in the last 60 days [13] - Resmed's fiscal 2026 EPS consensus estimate of $10.84 reflects a 13.5% improvement over 2025, with a 3.3% increase in estimates over the past 60 days [15] - In the last 12 months, BSX shares have increased by 6.8%, while RMD shares have risen by 5.8% [16] Investment Considerations - Boston Scientific is highlighted for its divisional strength, ongoing momentum with the WATCHMAN device, and strategic acquisitions in high-growth markets [18] - Resmed remains focused on innovation and strong demand for its products, but Boston Scientific is currently viewed as the more attractive investment option based on recent performance [18] - Boston Scientific holds a Zacks Rank 2 (Buy), while Resmed has a Zacks Rank 3 (Hold) [20]

Core Insights - Boston Scientific (BSX) is set to report its third-quarter 2025 results on October 22, with expectations of strong performance based on previous earnings surpassing estimates [1][8] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for BSX's Q3 2025 revenues is $4.97 billion, reflecting an 18.1% increase from the same quarter last year [2] - The consensus estimate for earnings per share (EPS) is 71 cents, indicating a 12.7% growth compared to the prior year's quarter [2][3] Group 2: Performance Drivers - The MedSurg division is expected to maintain solid sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is anticipated to benefit from core franchises and the expanded indication for Rezum, alongside progress from the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends in Deep Brain Stimulation continuing into Q3 [6] - The Cardiovascular segment is projected to perform well, with strong contributions from the Interventional Cardiology Therapies unit and the completion of the SoniVie acquisition [8][9] - The Peripheral Interventions unit is expected to show strong performance, bolstered by recent acquisitions and growth in both arterial and venous product lines [12] Group 3: Market Position and Trends - The MedSurg revenues are estimated at $1.70 billion, suggesting a 15% year-over-year increase [7] - Cardiovascular revenues are expected to improve by 19.6% year over year to $3.27 billion [13] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook [15]

Core Insights - Boston Scientific (BSX) is expected to report its second-quarter 2025 results on July 23, with prior EPS of 75 cents exceeding estimates by 11.94% [1] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 8.79% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for BSX's Q2 2025 revenues is $4.89 billion, reflecting an 18.7% increase year-over-year [2] - The EPS estimate for Q2 2025 is projected at 72 cents, indicating a 16.1% rise compared to the previous year [2] Performance Influencers - The MedSurg division is anticipated to maintain strong sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is expected to benefit from its core stone management franchise and the integration of the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends from Deep Brain Stimulation and the Intercept product [6] Segment Performance - MedSurg revenues are estimated at $1.68 billion, a 13.1% year-over-year increase [7] - The Cardiovascular unit is projected to perform well, with revenues expected to rise 8.3% year-over-year to $719.95 million [14] - Key contributors to Cardiovascular growth include the AGENT Drug-Coated Balloon and the completion of the SoniVie acquisition [10][11] Earnings Expectations - Boston Scientific has an Earnings ESP of +0.88%, indicating a higher likelihood of beating estimates [15] - The company holds a Zacks Rank of 2 (Buy), suggesting favorable conditions for earnings performance [16]

Core Viewpoint - Boston Scientific (BSX) has demonstrated strong performance with a 42.4% increase in share price over the past year, significantly outperforming the industry growth of 8.5% and the S&P 500's 10.6% increase, indicating solid fundamentals and growth opportunities for investors [1] Company Overview - Boston Scientific manufactures medical devices and products for various interventional medical specialties globally, having reorganized its operational structure into two reportable segments: MedSurg and Cardiovascular [2][3] Segment Performance - The Cardiovascular segment includes the Cardiology division and Peripheral Interventions, while the MedSurg group consists of Endoscopy, Urology, and Neuromodulation [3] Growth Drivers - The upward trend in BSX's share price is driven by the strong performance of the WATCHMAN left atrial appendage closure device, with the next-generation WATCHMAN FLX and FLX Pro capturing significant market share [4] - The launch of the FARAPULSE Pulsed Field Ablation System and commercial excellence across various businesses are also contributing to share price growth, supported by a solid fourth-quarter performance and increasing revenues from both reportable segments [5] Strategic Acquisitions - Investors are optimistic about BSX's strategic acquisitions in 2024, including Axonics, Inc., Intera Oncology Inc., and Cortex, Inc., which are expected to bolster the company's market position [6][7] International Expansion - Boston Scientific's international expansion remains strong, with emerging markets showing robust growth despite geopolitical challenges, and the launch of the next-generation accurate Prime Valve in Europe [8] - The FARAPULSE uptake in the EMEA region and strong growth in the Asia Pacific, particularly in China, Japan, Australia, and New Zealand, contributed to revenue increases of 10.8% in EMEA and 11.1% in Asia Pacific during the fourth quarter [9] Financial Performance - For the fourth quarter of 2024, BSX reported a 27.9% rise in the cost of products sold, leading to a 138-basis points contraction in gross margin due to macroeconomic headwinds and supply chain disruptions [10] - The company is also exposed to currency fluctuations, with expectations of a 100-basis point headwind from foreign exchange on revenues for 2025 [11] Earnings Estimates - The Zacks Consensus Estimate for BSX's 2025 EPS has increased by 0.7% to $2.85, with an earnings yield of 2.9%, outperforming the industry's 1.2% [12]